Chime Biologics and Mabgeek have completed PPQ for MG-K10 antibody, moving it to Phase III trials for Th2-mediated inflammatory diseases like COPD, AD, and asthma. The partnership aims to expedite development, ensuring regulatory compliance and quality standards.